Biocure Technology Inc.

Recent News

  • Biocure Shares DTC Eligible

    Vancouver, British Columbia--(Newsfile Corp. - February 7, 2019) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that its OTCQB-listed common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.DTC is a ...

    2019-02-07 10:00 AM ET
  • Biocure Signs a Collaboration Agreement with Y Biologics

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) -  Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the "Company" or "Biocure") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a collaboration agreement with Y Biologics ("YB"), a private R&D company in Korea who is ...

    2019-01-14 10:00 AM ET
  • Biocure Operations Report

    2018 In BriefPositive Pre-Clinical Trial Results on Leukemia CAR-T Cell Therapy DevelopmentSuccessful Toxicity Tests on Multiple Sclerosis TreatmentAcquired 6,060 Square Meters Land for Biosimilar Manufacturing Facilities

    2018-11-19 10:15 AM ET
  • Biocure Announces: Breakthrough Pre-Clinical Trial Results for CAR-T Cells Treatment of Acute Leukemia

    The trial was conducted under Korea FDA guidelines and represents the first anti-CD19 CAR-T cell immunotherapy in Korean historyCompany plans clinical trials already in 2019 with possible commercialization in 2020Dr. Sang Mok Lee, CEO commented, "This is a major milestone

    2018-10-16 10:22 AM ET